{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:00:39Z","timestamp":1794373239916,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science and Technology Commission of the Shanghai Municipality","award":["14411961800"],"award-info":[{"award-number":["14411961800"]}]},{"name":"National Health and Family Planning Commission of Shanghai","award":["20144Y0264"],"award-info":[{"award-number":["20144Y0264"]}],"id":[{"id":"https:\/\/ror.org\/052eegr76","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12886-019-1059-4","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T08:05:10Z","timestamp":1551168310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients"],"prefix":"10.1186","volume":"19","author":[{"given":"Kang","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-7857","authenticated-orcid":false,"given":"Jiang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"issue":"4","key":"1059_CR1","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/archopht.120.4.460","volume":"120","author":"CL Shields","year":"2002","unstructured":"Shields CL, Honavar SG, Shields JA, et al. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol. 2002;120(4):460\u20134.","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"1059_CR2","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1001\/archophthalmol.2011.150","volume":"129","author":"CL Shields","year":"2011","unstructured":"Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report no 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol. 2011;129(11):1399\u2013406.","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"1059_CR3","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/bjophthalmol-2011-301450","volume":"96","author":"FL Munier","year":"2012","unstructured":"Munier FL, Gaillard M-C, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96(8):1078\u201383.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"1059_CR4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jamaophthalmol.2014.414","volume":"132","author":"F Ghassemi","year":"2014","unstructured":"Ghassemi F, Shields CL, Ghadimi H, et al. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol. 2014;132(8):936\u201341.","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"1059_CR5","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archophthalmol.2012.1983","volume":"130","author":"F Ghassemi","year":"2012","unstructured":"Ghassemi F, Shields CL. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130(10):1268\u201371.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"1059_CR6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/bjophthalmol-2013-303885","volume":"98","author":"SJ Smith","year":"2014","unstructured":"Smith SJ, Smith BD, Mohney BG. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2014;98(3):292\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"1059_CR7","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.ophtha.2011.02.005","volume":"118","author":"T Kivel\u00e4","year":"2011","unstructured":"Kivel\u00e4 T, Eskelin S, Paloheimo M. Intravitreal methotrexate for retinoblastoma. Ophthalmology. 2011;118(8):1689.","journal-title":"Ophthalmology"},{"issue":"12","key":"1059_CR8","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.ophtha.2017.05.034","volume":"124","author":"JL Berry","year":"2017","unstructured":"Berry JL, Bechtold M, Shah S, et al. Not all seeds are created equal: seed classification is predictive of outcomes in retinoblastoma. Ophthalmology. 2017;124(12):1817\u201325.","journal-title":"Ophthalmology"},{"key":"1059_CR9","doi-asserted-by":"publisher","unstructured":"Berry JL, Shah S, Bechtold M. et al, Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era. Pediatr Blood Cancer. 2017;64(12). https:\/\/doi.org\/10.1002\/pbc.26696 .","DOI":"10.1002\/pbc.26696"},{"issue":"4","key":"1059_CR10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.5301\/ejo.5000921","volume":"27","author":"H Kiratli","year":"2017","unstructured":"Kiratli H, Ko\u00e7 \u0130, Varan A, Aky\u00fcz C. Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma. Eur J Ophthalmol. 2017;27(4):423\u20137.","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"1059_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/jamaophthalmol.2013.7666","volume":"132","author":"CL Shields","year":"2014","unstructured":"Shields CL, Manjandavida FP, Arepalli S, et al. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol. 2014;132(3):319\u201325.","journal-title":"JAMA Ophthalmol."},{"issue":"6","key":"1059_CR12","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.ophtha.2015.01.017","volume":"122","author":"JH Francis","year":"2015","unstructured":"Francis JH, Abramson DH, Gaillard MC, et al. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology. 2015;122(6):1173\u20139.","journal-title":"Ophthalmology"},{"issue":"4","key":"1059_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3109\/13816810.2014.973045","volume":"35","author":"FL Munier","year":"2014","unstructured":"Munier FL. Classification and management of seeds in retinoblastoma. Ellsworth lecture Ghent august 24th 2013. Ophthalmic Genet. 2014;35(4):193\u2013207.","journal-title":"Ophthalmic Genet"},{"issue":"7","key":"1059_CR14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/pbc.23002","volume":"57","author":"YJ Gao","year":"2011","unstructured":"Gao YJ, Qian J, Yue H, et al. Clinical characteristics and treatment outcome of children with intraocular retinoblastoma: a report from a Chinese cooperative group. Pediatr Blood Cancer. 2011;57(7):1113\u20136.","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"1059_CR15","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/bjophthalmol-2016-310056","volume":"101","author":"K Xue","year":"2017","unstructured":"Xue K, Liu A, Hui R, et al. Retrobulbar ocular blood flow changes measured by color Doppler imaging after intra-arterial chemotherapy in retinoblastoma. Br J Ophthalmol. 2017;101(10):1419\u201322.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"1059_CR16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1136\/bjophthalmol-2011-301016","volume":"96","author":"FL Munier","year":"2012","unstructured":"Munier FL, Soliman S, Moulin AP, et al. Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track. Br J Ophthalmol. 2012;96(8):1084\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"1059_CR17","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.ophtha.2006.06.018","volume":"113","author":"CL Shields","year":"2006","unstructured":"Shields CL, Mashayekhi A, Au AK. Et al. the international classification of retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276\u201380.","journal-title":"Ophthalmology"},{"issue":"1","key":"1059_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000448718","volume":"3","author":"HA Aziz","year":"2017","unstructured":"Aziz HA, Kim JW, Munier FL, et al. Acute hemorrhagic retinopathy following intravitreal melphalan injection for retinoblastoma report of two cases and technical modifications to enhance the prevention of retinal toxicity. Ocul Oncol Pathol. 2017;3(1):34\u201340.","journal-title":"Ocul Oncol Pathol"},{"issue":"6","key":"1059_CR19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2174\/1566524015999150804104144","volume":"15","author":"P Yang","year":"2015","unstructured":"Yang P. Editorial:uveitis: pathology Molecular Mechanisms and Therapy. Curr Mol Med. 2015;15(6):510.","journal-title":"Curr Mol Med"},{"issue":"4","key":"1059_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ophtha.2016.12.015","volume":"124","author":"JH Francis","year":"2017","unstructured":"Francis JH, Brodie SE, Marr B, et al. Efficacy and toxicity of Intravitreous chemotherapy for retinoblastoma: four-year experience. Ophthalmology. 2017;124(4):488\u201395.","journal-title":"Ophthalmology"},{"issue":"4","key":"1059_CR21","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/bjophthalmol-2017-310641","volume":"102","author":"R Rao","year":"2018","unstructured":"Rao R, Honavar SG, Sharma V, Reddy VAP. Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma. Br J Ophthalmol. 2018;102(4):490\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"1059_CR22","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/j.ophtha.2014.03.028","volume":"121","author":"JH Francis","year":"2014","unstructured":"Francis JH, Schaiquevich P, Buitrago E, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014;121(9):1810\u20137.","journal-title":"Ophthalmology"},{"key":"1059_CR23","doi-asserted-by":"crossref","unstructured":"S\u00fcsskind D, Hagemann U, Schrader M, et al. Toxic effects of melphalan, topotecan and carboplatin on retinal pigment epithelial cells. Acta Ophthalmol. 2016, 94(5):471\u20138.","DOI":"10.1111\/aos.12990"},{"issue":"1","key":"1059_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12886-016-0204-6","volume":"16","author":"AN Chao","year":"2016","unstructured":"Chao AN, Kao LY, Liu L, et al. diffuse chorioretinal atrophy after a single standard low- dose intravitreal melphalan injection in a child with retinoblastoma: a case report. BMC Ophthalmol. 2016;16(1):27.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"1059_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s10384-015-0378-0","volume":"59","author":"S Suzuki","year":"2015","unstructured":"Suzuki S, Aihara Y, Fujiwara M, et al. Intravitreal injection of melphalan for intraocular retinoblastoma. Jpn J Ophthalmol. 2015;59(3):164\u201372.","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"1059_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ophtha.2009.07.041","volume":"117","author":"T Sato","year":"2010","unstructured":"Sato T, Emi K, Ikeda T, et al. Severe intraocular inflammation after intravitreal injection of bevacizumab. Ophthalmology. 2010;117(3):512\u20136.","journal-title":"Ophthalmology"},{"issue":"4","key":"1059_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3109\/09273948.2010.490630","volume":"18","author":"SA Bayar","year":"2010","unstructured":"Bayar SA, Altinors DD, Kucukerdonmez C, et al. Severe corneal changes following intravitreal injection of bevacizumab. Ocul Immunol Inflamm. 2010;18(4):268\u201374.","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"1059_CR28","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1001\/jamaophthalmol.2015.3119","volume":"133","author":"JH Francis","year":"2015","unstructured":"Francis JH, Marr BP, Brodie SE, et al. Anterior ocular toxicity of intravitreous melphalan for retinoblastoma. JAMA Ophthalmol. 2015;133(12):1459\u201363.","journal-title":"JAMA Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1059-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-019-1059-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1059-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T11:31:07Z","timestamp":1606563067000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-019-1059-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1059"],"URL":"https:\/\/doi.org\/10.1186\/s12886-019-1059-4","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"assertion":[{"value":"25 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Institutional Review Board at Eye, Ear, Nose, and Throat Hospital of Fudan University approved this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. Images in our article are entirely unidentifiable and there are no details on individuals reported within the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interests exist.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"61"}}